Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ipilimumab |
Synonyms | |
Therapy Description |
Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ipilimumab | Yervoy | BMS-734016 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01274338 | Phase III | Ipilimumab Interferon alpha-2b | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT02239900 | Phase Ib/II | Ipilimumab | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | Completed | USA | 0 |
NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 13 |
NCT01497808 | Phase Ib/II | Ipilimumab | RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma | Completed | USA | 0 |
NCT01703507 | Phase I | Ipilimumab | Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases | Completed | USA | 0 |
NCT02117362 | Phase I | Ipilimumab Belapectin | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT03445533 | Phase III | Ipilimumab IMO-2125 + Ipilimumab | A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) | Terminated | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 0 |
NCT02221739 | Phase II | Ipilimumab | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01708941 | Phase II | Interferon alpha-2b Ipilimumab | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01804465 | Phase II | Ipilimumab | A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer | Completed | USA | 0 |
NCT01409174 | Phase Ib/II | Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | Terminated | USA | 0 |
NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03110107 | Phase Ib/II | Ipilimumab BMS-986218 + Nivolumab BMS-986218 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Terminated | USA | ROU | POL | NOR | NLD | ITA | ISR | FRA | FIN | ESP | DEU | CHE | CAN | BEL | AUS | ARG | 1 |
NCT01176474 | Phase I | NY-ESO-1 peptide vaccine Ipilimumab Nivolumab | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Completed | USA | 0 |
NCT01585194 | Phase II | Ipilimumab Nivolumab | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Completed | USA | 0 |
NCT02054520 | Phase II | Ipilimumab | Immunotherapy Study for Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT01950390 | Phase II | Ipilimumab Bevacizumab + Ipilimumab | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01970527 | Phase II | Ipilimumab | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT03070392 | Phase II | Dacarbazine Ipilimumab Pembrolizumab Tebentafusp | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
NCT02115243 | Phase I | Ipilimumab | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | Completed | USA | 0 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
NCT02530463 | Phase II | Nivolumab Azacitidine Ipilimumab | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | 0 |
NCT04697576 | Phase I | Nivolumab Pembrolizumab Ipilimumab | Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma | Recruiting | USA | 0 |
NCT05401786 | Phase II | Cemiplimab Ipilimumab | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) | Recruiting | NLD | 0 |
NCT01810016 | Phase I | Ipilimumab NY-ESO-1 peptide vaccine | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | Terminated | USA | AUS | 0 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
NCT01688492 | Phase Ib/II | Abiraterone + Prednisone Ipilimumab | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02311920 | Phase I | Temozolomide Nivolumab Ipilimumab | Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Completed | USA | 0 |
NCT03033576 | Phase II | Ipilimumab Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02500797 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma | Completed | USA | 0 |
NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Completed | 0 | |
NCT02027935 | Phase II | Aldesleukin Cyclophosphamide Ipilimumab | Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 | Completed | USA | 0 |
NCT02519322 | Phase II | Ipilimumab Nivolumab | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma | Completed | USA | 0 |
NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01896869 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab | A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Completed | USA | ROU | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 1 |
NCT02452281 | Phase Ib/II | Vitespen Ipilimumab | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | Withdrawn | USA | 0 |
NCT02060188 | Phase Ib/II | Nivolumab Ipilimumab | A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | Completed | USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS | 0 |
NCT03166397 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | Recruiting | ISR | 0 |
NCT02506114 | Phase II | PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | Terminated | USA | 0 |
NCT03600155 | Phase I | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02097732 | Phase II | Ipilimumab | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | Terminated | USA | 0 |
NCT02307149 | Phase I | Coxsackievirus A21 Ipilimumab | Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma | Completed | USA | 0 |
NCT03477864 | Phase I | Ipilimumab Cemiplimab + Ipilimumab Cemiplimab | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | Withdrawn | 0 | |
NCT02259231 | Phase Ib/II | Ipilimumab Nivolumab Omaveloxolone | RTA 408 Capsules in Patients With Melanoma - REVEAL | Completed | USA | 0 |
NCT01498978 | Phase II | Ipilimumab | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02113657 | Phase II | Ipilimumab | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT01950195 | Phase I | Ipilimumab | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | Terminated | USA | 0 |
NCT04093323 | Phase II | alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod Ipilimumab unspecified PD-L1 antibody unspecified PD-1 antibody | Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | Recruiting | USA | 0 |
NCT02009397 | Phase Ib/II | Sargramostim Ipilimumab | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | Completed | USA | 0 |
NCT02737475 | Phase Ib/II | Ipilimumab BMS-986178 Nivolumab | Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ITA | ISR | ESP | CAN | 0 |
NCT01740297 | Phase Ib/II | Ipilimumab Talimogene laherparepvec | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Completed | USA | FRA | DEU | 0 |
NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Completed | USA | 0 |
NCT02107755 | Phase II | Ipilimumab | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02731729 | Phase II | Ipilimumab Nivolumab | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | Completed | USA | 0 |
NCT01449279 | Phase I | Ipilimumab | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | Completed | USA | 0 |
NCT02020070 | Phase II | Ipilimumab Degarelix | Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | Active, not recruiting | USA | 0 |
NCT04635735 | Phase Ib/II | Ipilimumab | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT01696045 | Phase II | Ipilimumab | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | Terminated | USA | GBR | FRA | ESP | DNK | DEU | BEL | 1 |
NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
NCT02339571 | Phase II | Sargramostim Nivolumab Ipilimumab | Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT02279862 | Phase II | Ipilimumab | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05074992 | Phase II | Ipilimumab | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio) | Terminated | GBR | 0 |
NCT01689974 | Phase II | Ipilimumab | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | Terminated | USA | 0 |
NCT02158520 | Phase II | Ipilimumab Bevacizumab + Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02703623 | Phase II | Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin | A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) | Active, not recruiting | USA | 0 |
NCT02385669 | Phase Ib/II | 6MHP vaccine Ipilimumab | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | Terminated | USA | 0 |
NCT02538666 | Phase III | Ipilimumab Nivolumab | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT02812524 | Phase I | Ipilimumab | Ipilimumab for Head and Neck Cancer Patients | Active, not recruiting | USA | 0 |
NCT02467361 | Phase Ib/II | Nivolumab Pembrolizumab Ipilimumab Napabucasin | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | Completed | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT01621490 | Phase I | Ipilimumab Nivolumab | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) | Completed | USA | NLD | ESP | 0 |
NCT02678572 | Phase III | Dacarbazine Ipilimumab Melphalan Pembrolizumab | Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
NCT01530984 | Phase II | Sargramostim Ipilimumab | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | Withdrawn | USA | 0 |
NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT02496208 | Phase I | Ipilimumab Cabozantinib + Nivolumab | Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT04131621 | Phase II | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) | Unknown status | DEU | 0 |
NCT02498600 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT01711515 | Phase I | Ipilimumab Cisplatin | Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer | Completed | USA | 0 |
NCT03690986 | Phase I | Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | Recruiting | USA | 0 |
NCT02073123 | Phase Ib/II | Ipilimumab Indoximod | Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Active, not recruiting | USA | 0 |
NCT04323046 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Recruiting | USA | ISR | CHE | AUS | 0 |
NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
NCT01565837 | Phase II | Ipilimumab | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | Unknown status | USA | 0 |
NCT02388906 | Phase III | Nivolumab Ipilimumab | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Completed | USA | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 4 |
NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Completed | USA | 0 |
NCT01701674 | Phase I | Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Active, not recruiting | USA | 0 |
NCT05188118 | Phase I | Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |